Follow RSS for latest reports on this topicOpsumit (Macitentan) - Market Research and Reports

OPSUMIT is an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group
I) to delay disease progression. Disease progression included: death, initiation of intravenous (IV) or subcutaneous prostanoids, or clinical
worsening of PAH (decreased 6-minute walk distance, worsened PAH symptoms and need for additional PAH treatment). OPSUMIT also reduced hospitalization for PAH.

For full details open - http://opsumit.com/

BioPortfolio's Easy Ordering System

  1. Search for the report you need from our store
  2. Make online payment with our easy checkout process
  3. Receive PDF report via email

Easy Online Payment or Pro Forma Invoice

We accept the following credit cards...



or can supply a pro-forma invoice if required.

Related Reports:

We found 4 reports that matched your search.

Refine your search, and find more matches, using the form above.

Additional Searches

You may also like to search separately for: Opsumit (Macitentan)

We Stock...

{STICKYFOOTERMOBILE}